MedTrace Logo

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

NCT00883415 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-05-21

Study results available
· View outcomes & findings →

Summary

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Conditions

Interventions

DRUG

Darbepoetin alfa

Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Jeffrey C Fink, MD MS · University of Maryland School of Medicine and Baltimore VA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883415 on ClinicalTrials.gov